APVO - Aptevo Therapeutics GAAP EPS of -$1.50 beats by $0.14
- Aptevo Therapeutics press release ( NASDAQ: APVO ): Q3 GAAP EPS of -$1.50 beats by $0.14 .
- Aptevo had cash, cash equivalents and restricted cash of $22.6 million as of September 30, 2022. This includes $0.4 million of restricted cash that was released in October 2022.
For further details see:
Aptevo Therapeutics GAAP EPS of -$1.50 beats by $0.14